• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心、随机、双盲比较两种透明质酸填充剂在亚洲人中中面部容积恢复中的作用:一项 2 年的扩展研究。

A multicenter, randomized, double-blind comparison of two hyaluronic acid fillers in mid-face volume restoration in Asians: A 2-year extension study.

机构信息

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Medytox Inc., Seoul, South Korea.

出版信息

Dermatol Ther. 2021 Mar;34(2):e14787. doi: 10.1111/dth.14787. Epub 2021 Feb 9.

DOI:10.1111/dth.14787
PMID:33476068
Abstract

The long-term effectiveness and safety of hyaluronic acid fillers in mid-face volume restoration in Asians remain unclear. The objective of this study was to compare the long-term effectiveness and safety of Neuramis Volume Lidocaine (SHAPE-NVL) and Juvederm Voluma with Lidocaine (VYC-20L) in mid-face volume restoration in Asians. Overall, 88 Korean subjects with moderate-to-severe age-related mid-face volume deficit on the Mid-Face Volume Deficit Scale (MFVDS) received SHAPE-NVL on one side and VYC-20L on the contralateral side of the face. Of the 81 subjects who completed the 48-week primary study, 69 subjects were enrolled in an extension study lasting 104  weeks. MFVDS score and global aesthetic improvement were assessed at each visit. Response was defined as a ≥1-point reduction in MFVDS. At weeks 36 and 48, the responder rates for SHAPE-NVL were 81.93% and 80.72%, while those for VYC-20L were 85.54% and 81.92%, respectively. At the 104-week visit, the responder rates were 73.91% and 72.46% for SHAPE-NVL and VYC-20L, respectively. No subjects experienced any serious adverse events during the trial. SHAPE-NVL and VYC-20L showed comparable longevity and safety in mid-face volume restoration over 2  years in Asians. Both had durable effects for up to 2  years with minimal safety concerns.

摘要

透明质酸填充剂在亚洲人中中面部容量恢复的长期效果和安全性尚不清楚。本研究的目的是比较 Neuramis Volume Lidocaine(SHAPE-NVL)和 Juvederm Voluma with Lidocaine(VYC-20L)在亚洲人中中面部容量恢复中的长期效果和安全性。 共有 88 名韩国受试者在 Mid-Face Volume Deficit Scale(MFVDS)上存在中度至重度年龄相关性中面部容量不足,一侧接受 SHAPE-NVL,另一侧接受 VYC-20L。 在完成 48 周主要研究的 81 名受试者中,有 69 名受试者参加了持续 104 周的扩展研究。每次就诊时评估 MFVDS 评分和整体美学改善。反应定义为 MFVDS 降低≥1 分。在第 36 和 48 周,SHAPE-NVL 的应答率分别为 81.93%和 80.72%,而 VYC-20L 的应答率分别为 85.54%和 81.92%。在第 104 周时,SHAPE-NVL 和 VYC-20L 的应答率分别为 73.91%和 72.46%。试验过程中无受试者发生任何严重不良事件。 在亚洲人中,2 年以上的时间里,SHAPE-NVL 和 VYC-20L 在中面部体积恢复中表现出相当的持久性和安全性。两者都具有长达 2 年的持久效果,且安全性问题极小。

相似文献

1
A multicenter, randomized, double-blind comparison of two hyaluronic acid fillers in mid-face volume restoration in Asians: A 2-year extension study.多中心、随机、双盲比较两种透明质酸填充剂在亚洲人中中面部容积恢复中的作用:一项 2 年的扩展研究。
Dermatol Ther. 2021 Mar;34(2):e14787. doi: 10.1111/dth.14787. Epub 2021 Feb 9.
2
"A Multi-center, randomized, double blinded, comparative study of two hyaluronic acid fillers for temporary restoration of mid-face volume in Asians".一项关于两种透明质酸填充剂用于亚洲人面部中部容量临时恢复的多中心、随机、双盲、对照研究
J Cosmet Dermatol. 2020 Jul;19(7):1619-1626. doi: 10.1111/jocd.13218. Epub 2019 Nov 26.
3
Safety and Effectiveness of Hyaluronic Acid Filler, VYC-20L, via Cannula for Cheek Augmentation: A Randomized, Single-Blind, Controlled Study.透明质酸填充剂 VYC-20L 经套管用于面颊填充的安全性和有效性:一项随机、单盲、对照研究。
Dermatol Surg. 2021 Dec 1;47(12):1590-1594. doi: 10.1097/DSS.0000000000003246.
4
Duration of effect by injection volume and facial subregion for a volumizing hyaluronic acid filler in treating midface volume deficit.用于治疗中面部容积不足的一种填充用透明质酸填充剂按注射量和面部亚区域划分的效果持续时间
Dermatol Surg. 2015 Aug;41(8):942-9. doi: 10.1097/DSS.0000000000000416.
5
Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, VYC-20L.采用透明质酸注射填充剂 VYC-20L 进行安全有效的颏部填充。
Dermatol Surg. 2021 Jan 1;47(1):80-85. doi: 10.1097/DSS.0000000000002795.
6
Chin reinforcement using the hyaluronic acid injectable filler VYC-20L and VYC-25L.使用透明质酸可注射填充剂 VYC-20L 和 VYC-25L 进行颏部加固。
J Cosmet Dermatol. 2024 Jul;23(7):2368-2372. doi: 10.1111/jocd.16290. Epub 2024 Mar 18.
7
Safety and Effectiveness of the Hyaluronic Acid Dermal Filler VYC-17.5L for Nasolabial Folds: Results of a Randomized, Controlled Study.透明质酸真皮填充剂VYC - 17.5L用于治疗鼻唇沟的安全性和有效性:一项随机对照研究的结果
Dermatol Surg. 2018 May;44(5):670-678. doi: 10.1097/DSS.0000000000001529.
8
Higher Responder Rates Observed With Live Participant Assessment Versus Photographic Assessment After VYC-20L Hyaluronic Acid Treatment for Chin Augmentation.在 VYC-20L 透明质酸颏部填充治疗后,通过活体评估观察到的应答者比例高于照片评估。
Aesthet Surg J. 2024 Apr 4;44(5):527-536. doi: 10.1093/asj/sjad348.
9
Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable Gel.使用VYC-25L透明质酸注射凝胶进行安全、有效的下巴和下颌修复。
Dermatol Surg. 2019 Oct;45(10):1294-1303. doi: 10.1097/DSS.0000000000001960.
10
Volumizing hyaluronic acid filler for midface volume deficit: 2-year results from a pivotal single-blind randomized controlled study.中面部容积缺失用容积型透明质酸填充剂:一项关键性单盲随机对照研究的 2 年结果。
Dermatol Surg. 2013 Nov;39(11):1602-12. doi: 10.1111/dsu.12343. Epub 2013 Oct 4.

引用本文的文献

1
Noninferiority Study Comparing the Efficacy and Safety of a New Hyaluronic Acid (HA) Filler Containing Lidocaine With an Existing HA Filler for the Treatment of Nasolabial Fold Wrinkles: A Randomized, Double-Blind, Split-Face Trial.比较含利多卡因的新型透明质酸(HA)填充剂与现有HA填充剂治疗鼻唇沟皱纹的疗效和安全性的非劣效性研究:一项随机、双盲、半脸试验。
J Cosmet Dermatol. 2025 Jul;24(7):e70309. doi: 10.1111/jocd.70309.
2
Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review.使用真皮填充剂进行面部皱纹矫正的安全性及潜在并发症:一项系统文献综述
Medicina (Kaunas). 2024 Dec 27;61(1):25. doi: 10.3390/medicina61010025.
3
Comment on: "Efficacy and Safety of Lyophilized Articular Cartilage Matrix as an Injectable Facial Filler".
关于《冻干关节软骨基质作为可注射面部填充剂的疗效和安全性》的评论
Aesthetic Plast Surg. 2021 Aug;45(4):1957-1958. doi: 10.1007/s00266-021-02194-7. Epub 2021 Mar 3.